Sanofi eyes RSV antibody for its next blockbuster while Dupixent brings in record sales

Sanofi’s RSV an­ti­body Bey­for­tus is still on track to reach block­buster sta­tus this year as the com­pa­ny ex­pands man­u­fac­tur­ing ca­pac­i­ty, ac­cord­ing to re­marks made Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

WuXi and BIO’s grip-and-grin

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

Read More »